Rhythm Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RYTM Nasdaq 2836 rhythmtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Rhythm Pharmaceuticals, Inc.

European Stocks Close Mostly Lower in Thursday Trading as Investors Parse Earnings Reports, US Elections, Rising Oil Prices - Nov 5th, 2026 9:55 am
RYTM Stock Clocks Best Day In Nearly 16 Months On AstraZeneca $10B Bid Report - Nov 4th, 2026 3:20 pm
Rhythm Pharmaceuticals stock surges 28% on AstraZeneca bid report - Nov 4th, 2026 2:53 pm
Could Rhythm Pharmaceuticals (RYTM) Be Too Pricey After Recent Funding? - Nov 4th, 2026 11:16 am
Rhythm Pharmaceuticals Stock In Focus After Earnings Beat And $750 Million Financing - Nov 4th, 2026 7:16 am
Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome - Nov 4th, 2026 6:00 am
What Does Rhythm Pharmaceuticals (RYTM) Mean With A $750 Million Financing Deal? - Nov 4th, 2026 3:20 am
Rhythm Pharmaceuticals (RYTM) Dropped, So What Is Behind The Fresh Attention? - Nov 4th, 2026 12:10 am
Rhythm Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary - Nov 3rd, 2026 8:25 pm
Rhythm Pharmaceuticals Inc (RYTM) Q3 2026 Earnings Call Highlights: Revenue Surges 29% on ... - Nov 3rd, 2026 8:04 pm
Rhythm Pharmaceuticals Q3 Earnings Call Highlights - Nov 3rd, 2026 12:14 pm
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Beats Revenue Estimates - Nov 3rd, 2026 5:15 am
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update - Nov 3rd, 2026 5:00 am
Rhythm Amends Bivamelagon Royalty Structure; Secures $750 million in Financing - Nov 3rd, 2026 2:01 am
Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement - Nov 2nd, 2026 7:59 pm
EnteroBiotix Appoints former GSK Chief Medical Officer Dr Murray Stewart to Board of Directors - Nov 2nd, 2026 6:00 am
CAMP4 Therapeutics Corporation (CAMP) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Oct 29th, 2026 7:00 am
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Oct 27th, 2026 7:00 am